miRNA-198
Discover miR-198:
A molecular fulcrum for tumor suppression4+9
What is miR-198?
miR-198 is a critical tumor-suppressor miRNA, naturally expressed in healthy tissues but markedly downregulated in most cancer types, resulting in the dysregulation of diverse oncogenic mechanisms.
Key Highlights:
- Central Role in Tumor Suppression: miR-198 directly suppresses multiple tumor-promoting genes associated with cancer aggressiveness.
- Broad Therapeutic Potential: Demonstrates effectiveness in reducing tumor growth, aggressiveness, and metastatic spread of various cancer types, including pancreatic, ovarian, colon, gastric, osteosarcoma, lung, kidney, cervical, and breast cancer.
- Reversal of Drug Resistance: Sensitizes drug-resistant cancers to chemotherapy agents, such as gemcitabine, cisplatin, temozolomide, doxorubicin, among others.
- Validated Preclinical Efficacy: Shows significant tumor suppression and improved survival in preclinical animal models.
- Clinical Relevance: The strong correlation between low miR-198 levels and poor patient outcomes underscores its potential as a therapeutic agent.
Why miR-198 is Special?
miR-198 acts as a multi-faceted therapeutic scaffold, targeting critical pathways in cancer progression:
- Broad Impact: Suppresses tumor growth and limits metastasis.
- Synergy with Existing Drugs: Combats resistance to drugs like Cisplatin, Doxorubicin, and Gemcitabine, making therapies effective again.
- Patent-Protected Innovation: Speratum Biopharma ensures miR-198 remains an exclusive and robust treatment option.
- Why It Matters: Speratum Biopharma leverages miR-198’s unique therapeutic potential by combining their proprietary Nano-In™ and NoPass™ delivery platforms, ensuring safety, precision, and efficacy.
How miR-198 Works?
miR-198 works by restoring its natural levels in tumors using synthetic mimics, effectively targeting:
miR-198 as a Tumor Suppressor
- Downregulated in Cancer: miR-198 is suppressed in most cancers, enabling overexpression of oncogenic factors driving tumor growth, migration, invasion, and drug resistance.
- Restoration Disrupts Oncogenic Pathways: Restoring miR-198 downregulates specific target genes simultaneously, halting tumor progression with a broad impact.
- Targets Tumor-Promoting Genes: Directly binds to mRNA of oncogenes, leading to degradation or preventing translation into proteins.
- Enhances Chemotherapy Sensitivity: Reduces drug resistance by targeting resistance-associated genes.
- Inhibits Metastasis: Suppresses factors that promote cancer cell migration and invasion.
As a master regulator, miR-198 simultaneously impacts multiple pathways, amplifying its tumor-suppressive effects and offering broad therapeutic potential.
Genes involved in proliferation:
Stops cancer cell division.
Genes controlling migration and invasion:
Prevents metastasis.
Genes linked to chemotherapy resistance:
Revives the effectiveness of existing drugs.
The Speratum Biopharma Difference
At Speratum Biopharma, we are revolutionizing cancer treatment with miR-198. By combining our proprietary delivery platforms, Nano-In™ and NoPass™, we ensure that miR-198 reaches its targets safely and efficiently.
Our platform technologies unlock the full potential of miR-198 to treat a broad range of solid tumors, paving the way for innovative, life-changing therapies.
US20220145290A1 Patent Pending
Substrate sequence design for RNAi-mediated multi-site regulation of genomic and non-genomic RNAs.
Explore More
Learn more about our ongoing research, clinical trials, and how we are using miR-198 to push the boundaries of precision oncology. Stay updated with our latest publications and innovations.